100 days. 15 executive orders. Some bold healthcare policies.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Mr. Matthew Majewski has a track record of providing life science clients with analytically based solutions to their strategic issues.
He has led a wide range of corporate and asset-specific strategy engagements, many of which have focused on pricing and market access. Mr. Majewski has deep experience in the specialty disease space and has provided insights to many clients with rare disease, oncology, and cell & gene therapy assets across the retail, specialty, and hospital channels. Prior to joining CRA, Mr. Majewski was a consultant at a biopharmaceutical organization where he developed and managed market strategies for pre-launch products and designed and managed market organizations.